Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Navidea tumbles on extended US FDA review for radioactive tracing agent

This article was originally published in Clinica

Executive Summary

Shares of Navidea Biopharmaceuticals, formerly known as Neoprobe, tumbled as low as 39 cents, down 12%, on 3 April, after the Dublin, Ohio-based firm said the US FDA extended by three months the Prescription Drug User Fee Act (PDUFA) action date for the new drug application (NDA) for the company's radioactive diagnostic tracing agent Lymphoseek (tilmanocept). The radiotracer is designed for use in intraoperative lymphatic mapping (ILM), a surgical oncology procedure used primarily in patients with breast cancer and melanoma to determine if disease has spread to the lymph nodes.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts